Meta AnalysisID 7689
新型冠状病毒肺炎患者抗栓治疗的疗效：随机对照临床试验的系统评价与Meta分析
CRD42023449125
This meta-analysis aims to systematically review and evaluate whether antithrombotic therapy could improve the prognosis of COVID-19 patients, and to determine the appropriate intensity of antithrombotic treatment for pa
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7689
- Evidence Id
- 16247
- Core Evidence Id
- 16247
- Source Meta Analysis Id
- 7683
- Herb2 Meta Analysis Id
- HBMA007683
- Crd Id
- CRD42023449125
- Title
- The Efficiency of Antithrombotic Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
- Review Question
- This meta-analysis aims to systematically review and evaluate whether antithrombotic therapy could improve the prognosis of COVID-19 patients, and to determine the appropriate intensity of antithrombotic treatment for patients at different stage of COVID-19.
- Study Type Included
- Only randomized controlled clinical trials were included.
- Condition Being Studied
- The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had evolved into a global pandemic, as a serious threat to human being and global health system. Apart from the damage to the respiratory system, emerging evidence suggested that COVID-19 was associated with hypercoagulability and increased thrombotic complications, leading to a higher risk of mortality. Antithrombotic therapy, including the use of anticoagulants and antiplatelet, had been widely investigated as a potential treatment option for preventing or managing thrombotic events among COVID-19 patients. However, the optimal antithrombotic strategy for COVID-19 remained uncertain due to conflicting results from various clinical trials, which might be due to the heterogeneous baseline severity, dosage of antithrombotic therapy and study design, etc. Recently, there were several published randomized controlled trials (RCTs) that had investigated the efficacy of antithrombotic therapies in both outpatient and hospitalized COVID-19 patients. Therefore, we conducted this meta-analysis to systematically review and evaluate whether antithrombotic therapy could improve the prognosis of COVID-19 patients, and to determine the appropriate intensity of antithrombotic treatment for patients at different stage of COVID-19.
- Participant
- Included adult patients with suspected or confirmed COVID-19, without any restriction on the stage of COVID-19
- Animal
- Human Disease Modelled
- Intervention
- The intervention group should receive antithrombotic therapy, including either anticoagulant therapy (Unfractionated heparin, low molecular weight heparin or direct oral anticoagulants, etc) or antiplatelet therapy (aspirin, clopidogrel, ticagrelor or ltrombopag, etc), at therapeutic dose or prophylactic dose
- Comparator Control
- The control group should be contemporaneous patients who received standard care or placebo. Furthermore, if the intervention group received a therapeutic dose of anticoagulation, the control group could include the patients who received prophylactic anticoagulation beyond the standard care.
- Main Outcome
- The primary outcome of this study was all-cause mortality at day 30
- Outcome Measure
- Additional Outcome
- Key secondary outcome was the occurrence of any thrombotic events, such as pulmonary embolism (PE), venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke (IS) and other thrombotic events. The incidence of each specific thrombotic event mentioned above was also part of the secondary outcome. Other secondary outcomes included the proportion of outpatients who required admission, and the proportion of patients experiencing disease progression. Disease progression was defined as any of the following occurs: 1) an exacerbation of the WHO 7 symptom score for at least 2 points; 2) requiring invasive mechanical ventilation or ECMO; 3) death. The safety outcomes encompassed the incidence of major bleeding and non major clinically relevant bleeding (NMCRB) or any other bleeding events, as defined by the International Society on Thrombosis and Haemostasis
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- COVID-19; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Prognosis; Transtheoretical Model
- Contact
- Zhenbei Qian [email protected]
- Organisational Affiliation
- Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University
- Funding Source
- The Ministry of Science and Technology of the People’s Republic of China. Grant number(s) State the funder, grant or award number and the date of award This study is supported by grant 2023YFC0872500 from the Ministry of Science and Technology of the People’s Republic of China.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-07-27
- Registration Date
- 2023-07-27
- Anticipated Start Date
- 2023-07-01
- Anticipated Completion Date
- 2023-08-31
- Title Cn
- 新型冠状病毒肺炎患者抗栓治疗的疗效：随机对照临床试验的系统评价与Meta分析
- Title En
- The Efficiency of Antithrombotic Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
- Bilingual Status
- complete